REX Shares Launches Peptide ETF to Capture Broader Market Exposure…

Event summary

REX Shares launched the REX Peptide ETF (PEPT) on October 14, 2026, targeting the peptide economy end-to-end.
The ETF tracks the VettaFi Peptide Index, which includes 36 global companies across therapeutics, manufacturing, nutraceuticals, and cosmeceuticals.
PEPT has an expense ratio of 0.65% and is listed on Nasdaq.
The peptide market is projected to reach $200 billion by 2030, with supply constraints currently limiting growth.

The big picture

The launch of PEPT comes as the peptide market is still in its early stages, with only a small fraction of the obese population currently treated with GLP-1 medications. The ETF aims to capture the entire peptide supply chain, from development to commercialization, positioning investors to benefit from the broader adoption of peptide-based therapies. The market's rapid growth and supply constraints highlight the strategic importance of this thematic investment.

What we're watching

Market Growth: Whether the peptide market can sustain its projected growth given current supply constraints.
Competitive Dynamics: How PEPT will differentiate itself from existing investments in Eli Lilly and Novo Nordisk.
Regulatory Risks: The impact of regulatory approval processes and clinical trial outcomes on the peptide industry.